Met Life Investment Management, LLC Travere Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 49,288 shares of TVTX stock, worth $780,721. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,288
Previous 44,711
10.24%
Holding current value
$780,721
Previous $778,000
13.5%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
99.9MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$141 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$121 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$119 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$79.4 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$76 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.02B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...